Last reviewed · How we verify
Fentanyl (F1)
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Acute postoperative pain, Chronic cancer pain, Chronic non-cancer pain (transdermal formulations).
At a glance
| Generic name | Fentanyl (F1) |
|---|---|
| Also known as | NaCl (C) |
| Sponsor | Oslo University Hospital |
| Drug class | Opioid agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain management, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Fentanyl activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and producing potent analgesic and euphoric effects. It is approximately 50–100 times more potent than morphine on a weight basis. The drug is widely used for acute and chronic pain management, as well as perioperative sedation and anesthesia.
Approved indications
- Acute postoperative pain
- Chronic cancer pain
- Chronic non-cancer pain (transdermal formulations)
- Perioperative anesthesia and sedation
Common side effects
- Respiratory depression
- Nausea and vomiting
- Constipation
- Dizziness and sedation
- Pruritus
- Hypotension
- Dependence and addiction risk
Key clinical trials
- Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl (PHASE4)
- Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl (F1) CI brief — competitive landscape report
- Fentanyl (F1) updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI